In pre-clinical models, Chronos Therapeutics’ patented compound RDC5 and CHR1 (originally identified via the Chronoscreen™)show significant effects on pre-clinical model systems of neurodegeneration. Both compounds appear to not only reduce the formation of visible aggregates but also promote the degradation of neuro-toxic proteins.

Share this post: